Thanks to a strategic partnership with the Foundation for Medical Innovations (SfM) and the Faculty of Medicine, researchers from Institute for Ophthalmic Research will bring three promising compounds closer to clinical use.

This parternership marks the launch of RD TREAT (Retinal Dystrophies Treatment), a comprehensive program aimed at translating decades of research into real hope for patients.

The program focuses on 3 key projects:

• 1 Gene replacement therapy for specific types of retinitis pigmentosa
• 2 pharmacological, mutation-independent therapies to protect retinal cells

These cutting-edge strategies aim to halt disease progression and preserve vision for those affected by rare, currently incurable conditions.

With over 400 clinical staff members and 160 researchers, Tübingen’s Eye Clinic and Research Institute for Opthalmology form a powerhouse of innovation. The RD TREAT program strengthens their already recognized global leadership in ophthalmic care.

A dedicated translational team, formed with SfM, ensures smooth coordination from lab discoveries to clinical application. 
The program is guided by:

• A 5-year strategic plan
• Streamlined decision-making processes
• Strong regulatory and project management support

Embedded within the Gene and RNA Therapy Center, RD TREAT serves as a pioneering model for personalized molecular therapies—potentially influencing treatments far beyond ophthalmology.

Contact

For media or research inquiries:
Prof. Dr. Marius Ueffing
Director, Research Institute of Ophthalmology
Spokesperson, RD TREAT
+49 (0)7071 29-84020
+49 (0)7071 29-4560
marius.ueffing@uni-tuebingen.de